Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection
Viruses · 19.04.2026 · 18 (4) · 477
DOI: 10.3390/v18040477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 19.04.2026. Verfasst von Raisa Eloise Barbu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biomedical Sciences, 'Dunărea de Jos' University of Galați, 800008 Galați, Romania. Hauptthemen laut MEDLINE: Hepatitis Delta Virus, Virus Internalization, Antiviral Agents, Hepatitis B, Chronic. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review critically examines the inhibition of viral entry as an emerging disease-modifying strategy in chronic hepatitis B (HBV) and delta (HDV) virus infection, with particular emphasis on bulevirtide, the first-in-class of the sodium taurocholate cotransporting polypeptide entry inhibitor. This paper summarizes the analysis of 7 clinical trials that either underpinned the registration of bulevirtide or are important European real-life trials. We synthesize virological, pathophysiological and clinical evidence, highlighting the impact of this novel bulevirtide-based therapy on virological control, liver inflammation, fibrosis dynamics and long-term prognosis, as well as the limitations of this therapy. The observation of these trials is a greater than 2 log decrease from baseline in hepatitis D virus ribonucleic acid (HDV RNA) in 54–92% of patients and normalization of alanine transaminase (ALT) in 48.8–74% of patients after 23–144 weeks of treatment, and a significant decrease in liver fibrosis, as quantified by Fibroscan, at 12 months of treatment. The conclusion of the study is that this therapy represents an important leap in the etiological approach to chronic HDV infection and in improving the prognosis of these patients, but future clinical studies are needed to define the criteria for discontinuation of therapy, the long-term impact, as well as studies targeting new therapies that can intervene in other stages of the HDV and HBV life cycle not only to achieve HDV RNA negativity but also HBsAg clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral School of Biomedical Sciences, 'Dunărea de Jos' University of Galați, 800008 Galați, Romania.
- Faculty of Medicine and Pharmacy, Research Centre in the Medical-Pharmaceutical Field, 'Dunărea de Jos' University of Galați, 800008 Galați, Romania.
- Clinical Medical Department, Faculty of Medicine and Pharmacy, 'Dunărea de Jos' University of Galați, 800008 Galați, Romania.
- 'Sf. Ioan' Clinical Hospital for Children, 800487 Galați, Romania.
- 'Sf. Cuv. Parascheva' Clinical Hospital of Infectious Diseases, 800179 Galați, Romania.
- Depatment of Morphofunctional Science, Faculty of Medicine and Pharmacy, 'Dunărea de Jos' University of Galați, 800008 Galați, Romania.
ORCID-Profile: Raisa Eloise Barbu, Roxana Elena Bogdan Goroftei, Valerii Lutenco, Elena Dumea, Liliana Baroiu
Zitieren
APA
Barbu, R. E., Ignat, M. D., Bogdan Goroftei, R. E., Baltă, A. A. Ș., Lutenco, V., Bulza, V., Stoian, V. I., Cambrea, S. C., Dumea, E., & Baroiu, L. (2026). Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection. Viruses, 18(4), 477. https://doi.org/10.3390/v18040477
Vancouver
Barbu RE, Ignat MD, Bogdan Goroftei RE, Baltă AAȘ, Lutenco V, Bulza V, et al. Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection. Viruses. 2026;18(4):477. doi:10.3390/v18040477
BibTeX
@article{Barbu2026,
author = {Barbu, Raisa Eloise and Ignat, Mariana Daniela and Bogdan Goroftei, Roxana Elena and Baltă, Alexia Anastasia Ștefania and Lutenco, Valerii and Bulza, Valentin and Stoian, Valerian Ionuț and Cambrea, Simona Claudia and Dumea, Elena and Baroiu, Liliana},
title = {Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection},
journal = {Viruses},
year = {2026},
volume = {18},
number = {4},
pages = {477},
doi = {10.3390/v18040477}
}
EUVIMED